Moderna Surges 125% YTD: mRNA Flu Vaccine Approval, Pipeline Expansion, and What's Driving the Rally

Moderna (NASDAQ: MRNA) has staged one of the most dramatic comebacks on Wall Street this year, with shares climbing 125.51% since January. The stock closed up 12% on Friday, June 26, capping a multi-week rally that began when shares were trading near $46 at the start of June.

The resurgence has been fueled by several converging catalysts — a landmark regulatory milestone, a sweeping corporate restructuring, and a series of pipeline announcements that reminded investors why Moderna was once a pandemic-era darling.

**FDA Advisory Panel Clears the Path for mRNA Flu Vaccine**

One of the biggest catalysts came on June 18, when the FDA's Vaccines and Related Biological Products Advisory Committee delivered a unanimous 9-0 vote in favor of mFLUSIVA (mRNA-1010), Moderna's mRNA-based seasonal influenza vaccine candidate. The committee determined that the product carries a favorable benefit-risk profile for adults aged 50 and older.

Unanimous verdicts from FDA advisory panels are exceptionally rare in the biotech space, and the decision significantly reduced regulatory uncertainty ahead of the official PDUFA decision date on August 5. Should the FDA grant approval, mFLUSIVA would become the first mRNA-based seasonal flu vaccine to receive a license in the United States — a historic milestone for the platform.

**Wall Street Remains Divided**

Despite the bullish price action, analyst sentiment on MRNA remains cautious. Piper Sandler raised its price target to $77, while Jefferies bumped its target to $53 but maintained a Hold rating. The consensus price target across Wall Street currently sits at just $43.45 — well below current trading levels.

Sixteen analysts currently maintain Hold ratings on the stock, reflecting broader skepticism about near-term revenue generation. Insider activity has also leaned bearish, with 75 recent transactions skewed toward selling. Most analysts do not expect meaningful flu-related revenues to materialize before 2027.

**Corporate Restructuring Adds Momentum**

Beyond the flu vaccine story, Moderna has been actively reshaping its business model. The company announced a restructuring of its operating framework around three core commercial franchises: vaccines, oncology, and rare diseases. That announcement alone sent shares up approximately 6.3%.

The move signals a deliberate effort to diversify beyond COVID-19, which once defined the company entirely. Moderna's all-time high of $497 was reached in August 2021, during the height of its COVID vaccine dominance.

**Science Day Showcases a Broader Pipeline**

On June 25, Moderna hosted a Science Day event that put the company's expansive research pipeline on full display. Highlights included in vivo CAR-T therapy programs and T-cell engager platforms targeting both oncology and autoimmune diseases — therapeutic areas with enormous long-term commercial potential.

Adding further fuel to the rally, Moderna announced plans to invest in German manufacturing facilities, including some sites that BioNTech has indicated it plans to close. Traders interpreted this as a strategic capacity expansion in anticipation of a significant product launch wave expected between 2027 and 2028. The news pushed MRNA shares up between 8% and 12% across multiple trading sessions.

**Bottom Line**

Moderna's 2025 comeback reflects a combination of regulatory progress, strategic reinvention, and renewed investor appetite for mRNA-platform stories. While Wall Street consensus remains skeptical and insider selling continues, the stock's momentum underscores how quickly sentiment can shift when catalysts align. The August 5 FDA decision on mFLUSIVA will likely be the next major test for the rally.